文献速递前列腺癌

帕博利珠单抗联合恩扎卢胺治疗恩扎卢胺进展的转移性去势抵抗性前列腺癌:2期KEYNOTE-199研究队列4和5

Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2024-08-12

KEYNOTE-199是一项多队列2期研究,评估帕博利珠单抗联合持续恩扎卢胺治疗未接受化疗且对恩扎卢胺初始应答后进展的转移性去势抵抗性前列腺癌(mCRPC)。队列4(RECIST可测量病灶,n=81)确认客观缓解率(ORR)为12.3%(95%CI 6.1-21.5%),疾病控制率(DCR)为53.1%(95%CI 41.7-64.3%),中位总生存期(OS)为17.6个月(95%CI 14.0-22.6);队列5(仅骨或骨为主病灶,n=45)DCR为51.1%(95%CI 35.8-66.3%),中位OS为20.8个月(95%CI 14.1-28.9)。≥3级治疗相关不良事件发生于35例(27.8%),队列4中2例死于免疫相关不良事件(肌无力综合征和吉兰-巴雷综合征)。结论认为该联合方案显示适度抗肿瘤活性且安全性可控。

要点

  • 队列4确认ORR为12.3%,中位缓解持续时间8.1个月,其中5例缓解持续≥6个月。
  • 队列4和队列5的DCR分别为53.1%和51.1%,中位OS分别为17.6个月和20.8个月。
  • ≥3级治疗相关不良事件发生率为27.8%,队列4中2例死于免疫相关不良事件。

核心结论

  • 在初始应答后恩扎卢胺进展的mCRPC患者中,帕博利珠单抗联合持续恩扎卢胺治疗显示出适度抗肿瘤活性和可控的安全性。

研究设计与样本

  • KEYNOTE-199(NCT02787005)是一项多队列2期研究,评估帕博利珠单抗治疗mCRPC患者。
  • 入组患者未接受过mCRPC化疗,且对恩扎卢胺初始应答后出现耐药(依据前列腺癌临床试验工作组3指南定义)。
  • RECIST可测量病灶患者入队列4(n=81),仅骨或骨为主病灶患者入队列5(n=45)。
  • 所有患者接受帕博利珠单抗200 mg每3周一次,最多35个周期,同时持续恩扎卢胺直至进展、不可接受毒性或退出。
  • 主要终点为队列4中盲法独立中心审查按RECIST v1.1评估的客观缓解率(ORR)。

主要发现

  • 共126例患者接受治疗(队列4 n=81,队列5 n=45),中位年龄72岁(范围43-92),87.3%在研究入组前接受恩扎卢胺≥6个月。
  • 队列4确认ORR为12.3%(95%CI 6.1-21.5%),中位缓解持续时间8.1个月(范围2.5+至15.2),其中5例客观缓解持续≥6个月。
  • 队列4的DCR为53.1%(95%CI 41.7-64.3%),队列5的DCR为51.1%(95%CI 35.8-66.3%)。
  • 队列4中位OS为17.6个月(95%CI 14.0-22.6),队列5中位OS为20.8个月(95%CI 14.1-28.9)。
  • ≥3级治疗相关不良事件发生于35例(27.8%);队列4中2例死于免疫相关不良事件(肌无力综合征和吉兰-巴雷综合征)。

关键数值与推荐

  • 队列4确认ORR为12.3%(95%CI 6.1-21.5%)。
  • 队列4的DCR为53.1%(95%CI 41.7-64.3%),队列5的DCR为51.1%(95%CI 35.8-66.3%)。
  • 队列4中位OS为17.6个月(95%CI 14.0-22.6),队列5中位OS为20.8个月(95%CI 14.1-28.9)。
  • ≥3级治疗相关不良事件发生于35例(27.8%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: KEYNOTE-199 (NCT02787005) is a multicohort phase 2 study evaluating pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC). Results from cohorts 4 (C4) and 5 (C5) are presented. METHODS: Eligible patients had not received chemotherapy for mCRPC and had responded to enzalutamide prior to developing resistance as defined by Prostate Cancer Clinical Trials Working Group 3 guidelines. Patients with RECIST-measurable disease were enrolled in C4, and patients with bone-only or bone-predominant disease were enrolled in C5. All patients received pembrolizumab 200 mg every 3 weeks for ≤35 cycles with ongoing enzalutamide until progression, unacceptable toxicity, or withdrawal. The primary end point was objective response rate (ORR) per RECIST v1.1 by blinded independent central review in C4. Secondary end points included disease control rate (DCR), overall survival, and safety in each cohort and both cohorts combined. RESULTS: A total of 126 patients were treated (C4, n = 81; C5, n = 45). Median age was 72 years (range 43-92), and 87.3% had received ≥6 months of enzalutamide prior to study entry. Confirmed ORR was 12.3% (95% CI 6.1-21.5%) for C4. Median duration of response in C4 was 8.1 months (range, 2.5+ to 15.2), and 5 of these patients experienced an objective response lasting ≥6 months. DCR was 53.1% (95% CI 41.7-64.3%) in C4 and 51.1% (95% CI 35.8-66.3%) in C5. Median overall survival was 17.6 months (95% CI 14.0-22.6) in C4 and 20.8 months (95% CI 14.1-28.9) in C5. Grade ≥3 treatment-related adverse events occurred in 35 patients (27.8%); 2 patients in C4 died from immune-related adverse events (myasthenic syndrome and Guillain-Barré syndrome). CONCLUSIONS: The addition of pembrolizumab to ongoing enzalutamide treatment in patients with mCRPC that progressed on enzalutamide after initial response demonstrated modest antitumor activity with a manageable safety profile. CLINICAL TRIAL REGISTRY AND ID: ClinicalTrials.gov, NCT02787005.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Graff JN, Hoimes CJ, Gerritsen WR, et al. Pembrolizumab plus enzalutamide for metastatic castration-resistant prostate cancer progressing on enzalutamide: cohorts 4 and 5 of the phase 2 KEYNOTE-199 study. Prostate Cancer Prostatic Dis. 2024. PMID: 39134652. doi:10.1038/s41391-024-00865-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。